menu
    • menu
    [{"orgOrder":0,"company":"GSK","sponsor":"Immutep","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"IMP731","moa":"LAG3 cell","graph1":"Immunology","graph2":"Phase II","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"GSK \/ Immutep","highestDevelopmentStatusID":"8","companyTruncated":"GSK \/ Immutep"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Brazikumab","moa":"Interleukin-23","graph1":"Immunology","graph2":"Phase II","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"Zura Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"Tibulizumab","moa":"Interleukin 17A | Tumor necrosis factor ligand superfamily member 13B","graph1":"Immunology","graph2":"Phase II","graph3":"Zura Bio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Zura Bio \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Zura Bio \/ Inapplicable"},{"orgOrder":0,"company":"Zura Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Tibulizumab","moa":"Interleukin 17A | Tumor necrosis factor ligand superfamily member 13B","graph1":"Immunology","graph2":"Phase II","graph3":"Zura Bio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Zura Bio \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Zura Bio \/ Inapplicable"},{"orgOrder":0,"company":"Zura Bio","sponsor":"Access Biotechnology","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Antibody","year":"2024","type":"Private Placement","leadProduct":"Tibulizumab","moa":"Interleukin 17A | Tumor necrosis factor ligand superfamily member 13B","graph1":"Immunology","graph2":"Phase II","graph3":"Zura Bio","amount2":0.11,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0.11,"dosageForm":"Injection","sponsorNew":"Zura Bio \/ Access Biotechnology","highestDevelopmentStatusID":"8","companyTruncated":"Zura Bio \/ Access Biotechnology"},{"orgOrder":0,"company":"Zura Bio","sponsor":"Deep Track Capital","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Antibody","year":"2023","type":"Private Placement","leadProduct":"Tibulizumab","moa":"Interleukin 17A | Tumor necrosis factor ligand superfamily member 13B","graph1":"Immunology","graph2":"Phase II","graph3":"Zura Bio","amount2":0.080000000000000002,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0.080000000000000002,"dosageForm":"Injection","sponsorNew":"Zura Bio \/ Deep Track Capital","highestDevelopmentStatusID":"8","companyTruncated":"Zura Bio \/ Deep Track Capital"},{"orgOrder":0,"company":"Zura Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Tibulizumab","moa":"Interleukin 17A | Tumor necrosis factor ligand superfamily member 13B","graph1":"Immunology","graph2":"Phase II","graph3":"Zura Bio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Zura Bio \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Zura Bio \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"AZD7798","moa":"CCR9","graph1":"Immunology","graph2":"Phase II","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Solution","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"AZD7798","moa":"CCR9","graph1":"Immunology","graph2":"Phase II","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Solution","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"IQVIA","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Benralizumab","moa":"Interleukin-5 receptor subunit alpha","graph1":"Immunology","graph2":"Phase II","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AstraZeneca \/ IQVIA","highestDevelopmentStatusID":"8","companyTruncated":"AstraZeneca \/ IQVIA"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Parexel","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"AZD7798","moa":"CCR9","graph1":"Immunology","graph2":"Phase II","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Solution","sponsorNew":"AstraZeneca \/ Parexel","highestDevelopmentStatusID":"8","companyTruncated":"AstraZeneca \/ Parexel"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"AZD7798","moa":"CCR9","graph1":"Immunology","graph2":"Phase II","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Solution","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"AZD7798","moa":"CCR9","graph1":"Immunology","graph2":"Phase II","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Solution","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"AstraZeneca \/ Inapplicable"}]

    Find Clinical Drug Development Pipelines & Deals | PipelineProspector

    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Zura Bio

                            United Kingdom arrow
                            Boulder Peptide
                            Not Confirmed

                            Zura Bio

                            United Kingdom arrow
                            Boulder Peptide
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Tibulizumab

                            Therapeutic Area : Immunology

                            Study Phase : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Tibulizumab Systemic Sclerosis Understanding and Response Evaluation (TibuSURE)

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Antibody

                            Upfront Cash : Inapplicable

                            February 24, 2025

                            Lead Product(s) : Tibulizumab

                            Therapeutic Area : Immunology

                            Highest Development Status : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Zura Bio

                            United Kingdom arrow
                            Boulder Peptide
                            Not Confirmed

                            Zura Bio

                            United Kingdom arrow
                            Boulder Peptide
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Tibulizumab

                            Therapeutic Area : Immunology

                            Study Phase : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Zura Bio Launches Phase 2 TibuSURE Study for Tibulizumab in Systemic Sclerosis

                            Details : ZB-106 (tibulizumab) is an humanized, tetravalent bispecific dual-antagonist antibody engineered to bind to and neutralize both IL-17A and BAFF, being investigated in systemic sclerosis (SSc).

                            Product Name : Undisclosed

                            Product Type : Antibody

                            Upfront Cash : Inapplicable

                            December 23, 2024

                            Lead Product(s) : Tibulizumab

                            Therapeutic Area : Immunology

                            Highest Development Status : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            AstraZeneca

                            United Kingdom arrow
                            Boulder Peptide
                            Not Confirmed

                            AstraZeneca

                            United Kingdom arrow
                            Boulder Peptide
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : AZD7798

                            Therapeutic Area : Immunology

                            Study Phase : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Study Evaluating AZD7798 for Treatment in Crohn's Disease Patients With an Ileostomy

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Antibody

                            Upfront Cash : Inapplicable

                            November 08, 2024

                            Lead Product(s) : AZD7798

                            Therapeutic Area : Immunology

                            Highest Development Status : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            AstraZeneca

                            United Kingdom arrow
                            Boulder Peptide
                            Not Confirmed

                            AstraZeneca

                            United Kingdom arrow
                            Boulder Peptide
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : AZD7798

                            Therapeutic Area : Immunology

                            Study Phase : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Phase IIa Study Evaluating AZD7798 in Crohn's Disease

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Antibody

                            Upfront Cash : Inapplicable

                            June 10, 2024

                            Lead Product(s) : AZD7798

                            Therapeutic Area : Immunology

                            Highest Development Status : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            GSK

                            United Kingdom arrow
                            Boulder Peptide
                            Not Confirmed

                            GSK

                            United Kingdom arrow
                            Boulder Peptide
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Belimumab

                            Therapeutic Area : Immunology

                            Study Phase : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Benlysta Granted Orphan Drug Designation by US FDA For the Potential Treatment of Systemic Sclerosis

                            Details : A fully human monoclonal antibody, Benlysta (belimumab) inhibits the prolonged survival of B cells induced by increased BLyS, including autoreactive B cells, and reduces the differentiation of B cells into immunoglobulin-producing plasma cells.

                            Product Name : Benlysta

                            Product Type : Antibody

                            Upfront Cash : Inapplicable

                            January 02, 2023

                            Lead Product(s) : Belimumab

                            Therapeutic Area : Immunology

                            Highest Development Status : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Akari Therapeutics

                            United Kingdom arrow
                            Boulder Peptide
                            Not Confirmed

                            Akari Therapeutics

                            United Kingdom arrow
                            Boulder Peptide
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Nomacopan

                            Therapeutic Area : Immunology

                            Study Phase : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Akari Therapeutics Announces Publication of Phase II Data of Investigational Nomacopan for the Treatment of Bu...

                            Details : Seven of nine patients responded to rVA576 (nomacopan) with three, regarded as complete responders, showing >80% reduction in BPDAI (BP disease activity index)activity and four patients showing >70% reduction in pruritis by day 42; two of nine patients w...

                            Product Name : Coversin

                            Product Type : Protein

                            Upfront Cash : Inapplicable

                            October 05, 2022

                            Lead Product(s) : Nomacopan

                            Therapeutic Area : Immunology

                            Highest Development Status : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            GSK

                            United Kingdom arrow
                            Boulder Peptide
                            Not Confirmed

                            GSK

                            United Kingdom arrow
                            Boulder Peptide
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : IMP731

                            Therapeutic Area : Immunology

                            Study Phase : Phase II

                            Sponsor : Immutep

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Immutep Announces that the Phase II Ulcerative Colitis Study of GSK2831781 Has Been Discontinued

                            Details : GSK, has stopped its Phase II trial of anti-LAG3 cell depleting monoclonal antibody, GSK2831781 (derived from Immutep’s IMP731 antibody), in patients with active ulcerative colitis. The trial was stopped based on the assessment of clinical data of plan...

                            Product Name : Undisclosed

                            Product Type : Antibody

                            Upfront Cash : Inapplicable

                            January 22, 2021

                            Lead Product(s) : IMP731

                            Therapeutic Area : Immunology

                            Highest Development Status : Phase II

                            Sponsor : Immutep

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Akari Therapeutics

                            United Kingdom arrow
                            Boulder Peptide
                            Not Confirmed

                            Akari Therapeutics

                            United Kingdom arrow
                            Boulder Peptide
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Nomacopan,Prednisone

                            Therapeutic Area : Immunology

                            Study Phase : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Akari Therapeutics Reports End-of-Phase II Meeting With FDA to Initiate Pivotal Phase III Study of Nomacopanfo...

                            Details : Treatment arms will be tapered to minimal OCS and an important secondary endpoint is reduction in cumulative OCS on nomacopan as high dose OCS are regarded as unsafe in this vulnerable patient population.

                            Product Name : Coversin

                            Product Type : Protein

                            Upfront Cash : Inapplicable

                            December 08, 2020

                            Lead Product(s) : Nomacopan,Prednisone

                            Therapeutic Area : Immunology

                            Highest Development Status : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            AstraZeneca

                            United Kingdom arrow
                            Boulder Peptide
                            Not Confirmed

                            AstraZeneca

                            United Kingdom arrow
                            Boulder Peptide
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Benralizumab

                            Therapeutic Area : Immunology

                            Study Phase : Phase II

                            Sponsor : IQVIA

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Study to Investigate the Use of Benralizumab in Patients With Chronic Spontaneous Urticaria Who Are Symptoma...

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Antibody

                            Upfront Cash : Inapplicable

                            November 03, 2020

                            Lead Product(s) : Benralizumab

                            Therapeutic Area : Immunology

                            Highest Development Status : Phase II

                            Sponsor : IQVIA

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Akari Therapeutics

                            United Kingdom arrow
                            Boulder Peptide
                            Not Confirmed

                            Akari Therapeutics

                            United Kingdom arrow
                            Boulder Peptide
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Nomacopan

                            Therapeutic Area : Immunology

                            Study Phase : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Akari Therapeutics to Present Phase II Data from Bullous Pemphigoid Trial at EADV Virtual Congress October 29

                            Details : The poster presentation will describe the safety & efficacy data from Akari’s Phase II clinical trial of nomacopan in adult patients with mild-moderate bullous pemphigoid. The PhII data was the basis for the agreement of the FDA & EMA that Akari may pr...

                            Product Name : Coversin

                            Product Type : Protein

                            Upfront Cash : Inapplicable

                            October 27, 2020

                            Lead Product(s) : Nomacopan

                            Therapeutic Area : Immunology

                            Highest Development Status : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth